Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of cisplatin + serplulimab + pirfenidone in previously treated advanced pancreatic cancer
ChiCTR2600133776Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, serplulimab and pirfenidone in pancreatic cancer (PC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started May 2023; status: recruiting.
02
Drugs
cisplatinserplulimabpirfenidone
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2600133776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133776.